How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,709 results for

Antibiotic Food Interactions

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Insights into the interactions between tetracycline, its degradation products and bovine serum albumin (PubMed)

Insights into the interactions between tetracycline, its degradation products and bovine serum albumin Tetracyclines (TCs) are the most widely used antibiotics in the world. Because antibiotics have low bioavailability and are difficult to completely remove using current sewage treatment facilities, residual TCs and their degradation products in the environment, animal and plant foodstuffs and personal care products may enter the body through the food chain, thus causing unpredictable effects (...) on human health. We studied bovine serum albumin (BSA) (a functional protein) as a target of tetracycline-induced toxicity by examining its interactions with TC, anhydrotetracycline (ATC) and epitetracycline (ETC), based on a fluorescence spectroscopy and molecular docking method under simulated physiological conditions. The interaction mechanism was elucidated at the molecular level. The results show that TC, ATC and ETC bind at site II of BSA and interact mainly through hydrogen bonding interactions

Full Text available with Trip Pro

2016 SpringerPlus

42. Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)

Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD) Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study (...) Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier

2016 Clinical Trials

43. Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects

Participant Data (IPD) Sharing Statement: Plan to Share IPD: Yes Keywords provided by CTI BioPharma: Drug-Interaction Study Additional relevant MeSH terms: Layout table for MeSH terms Rifampin Cytochrome P-450 CYP3A Inducers Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents Anti-Infective Agents Leprostatic Agents Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Cytochrome P-450 CYP2B6 Inducers Cytochrome P-450 Enzyme Inducers (...) Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2016 Clinical Trials

44. Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients

adherence to antiretroviral treatment (<90% during the last week) Patients who are taking or have been taking any other medication within the last two weeks prior to be recruited in the study, including herbal medicines and food supplements, with known interactions with darunavir, cobicistat or etravirine (i.e St. John's wort, grapefruit juice, some antibiotics such as erythromycin or rifampicin; antiepileptics such as phenytoin, phenobarbital or carbamazepine; antifungals such as itraconazole (...) Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2016 Clinical Trials

45. Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin

Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02854748 Recruitment Status : Unknown Verified August 2016 by Chong Kun Dang Pharmaceutical. Recruitment status was: Not yet recruiting First Posted : August 3, 2016 Last Update

2016 Clinical Trials

46. Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Clarithromycin, Amoxicillin and Ilaprazole

Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Clarithromycin, Amoxicillin and Ilaprazole Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Clarithromycin, Amoxicillin and Ilaprazole - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Clarithromycin, Amoxicillin and Ilaprazole (DDI) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02998437 Recruitment Status : Completed First Posted : December 20, 2016

2016 Clinical Trials

47. Interactions of Human Gut Microbiota With Intestinal Sweet Taste Receptors

Interactions of Human Gut Microbiota With Intestinal Sweet Taste Receptors Interactions of Human Gut Microbiota With Intestinal Sweet Taste Receptors - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Interactions of Human Gut Microbiota With Intestinal Sweet Taste Receptors (ISTAR-micro) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03032640 Recruitment Status : Active, not recruiting First Posted : January 26, 2017 Last Update Posted : February 15, 2019 Sponsor: Translational Research Institute

2016 Clinical Trials

48. Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy Subjects

Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy Subjects Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy Subjects - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study (...) Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy Subjects The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S

2016 Clinical Trials

49. Diet Interactions With Human Gut Microbiota. The Potential Role of Mediterranean Diet Adherence. DIAGRAM, a Pilot Study

Population european populations Criteria Inclusion Criteria: Aged 40 to 60 years Healthy (apparently free of diseases) Moderately physically active Habitually eating foods representative of their community (Cretan diet, Italian Mediterranean diet, French Auvergnat diet). The assessment of the consumption of such food will be based to a detailed dietary history retrieved by a nutrition specialist) Exclusion Criteria: Following any kind of treatment, notably antibiotics the last 3 months Sedentary (...) Diet Interactions With Human Gut Microbiota. The Potential Role of Mediterranean Diet Adherence. DIAGRAM, a Pilot Study Diet Interactions With Human Gut Microbiota. The Potential Role of Mediterranean Diet Adherence. DIAGRAM, a Pilot Study - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2016 Clinical Trials

50. Shape Changes and Interaction Mechanism of Escherichia coli Cells Treated with Sericin and Use of a Sericin-Based Hydrogel for Wound Healing (PubMed)

Shape Changes and Interaction Mechanism of Escherichia coli Cells Treated with Sericin and Use of a Sericin-Based Hydrogel for Wound Healing To verify the interaction mechanism between sericin and Escherichia coli, especially the morphological and structural changes in the bacterial cells, the antimicrobial activity of sericin against E. coli as a model for Gram-negative bacteria was investigated. The antibacterial activity of sericin on E. coli and the interaction mechanism were investigated (...) the permeability of the cell membrane. A sericin-based hydrogel was prepared for an in vivo study of wound dressing. The results showed that the antibacterial activity of the hydrogel increased with the increase in the concentration of sericin from 10 g/liter to 40 g/liter. The introduction of sericin induces membrane blebbing of E. coli cells caused by antibiotic action on the cell membrane. The cytoplasm shrinkage phenomenon was accompanied by blurring of the membrane wall boundaries. When E. coli cells were

Full Text available with Trip Pro

2016 Applied and environmental microbiology

51. Present understanding of the interaction of drugs and food during absorption. (PubMed)

Present understanding of the interaction of drugs and food during absorption. 4915744 1970 10 05 2018 11 13 0008-4409 103 4 1970 Aug 15 Canadian Medical Association journal Can Med Assoc J Present understanding of the interaction of drugs and food during absorption. 360-4 Krondl A A eng Journal Article Review Canada Can Med Assoc J 0414110 0008-4409 0 Anti-Bacterial Agents 0 Anticholesteremic Agents 0 Anticonvulsants 0 Antineoplastic Agents 0 Cathartics 0 Pharmaceutical Preparations 0 Surface (...) -Active Agents AIM IM Anti-Bacterial Agents pharmacology Anticholesteremic Agents Anticonvulsants pharmacology Antineoplastic Agents pharmacology Biological Transport, Active Cathartics pharmacology Diffusion Digestive System enzymology Food Gastric Juice Gastric Mucosa physiology Humans Intestinal Absorption drug effects Intestinal Secretions Lipid Metabolism Pharmaceutical Preparations metabolism Solubility Surface-Active Agents pharmacology 72 1970 8 15 1970 8 15 0 1 1970 8 15 0 0 ppublish 4915744

Full Text available with Trip Pro

1970 Canadian Medical Association Journal

52. Antibiotics as part of the management of severe acute malnutrition. (PubMed)

% confidence interval [CI], 1.04 to 1.68; relative risk with placebo vs. cefdinir, 1.64; 95% CI, 1.27 to 2.11). The mortality rates for the three groups were 4.8%, 4.1%, and 7.4%, respectively (relative risk of death with placebo vs. amoxicillin, 1.55; 95% CI, 1.07 to 2.24; relative risk with placebo vs. cefdinir, 1.80; 95% CI, 1.22 to 2.64). Among children who recovered, the rate of weight gain was increased among those who received antibiotics. No interaction between type of severe acute malnutrition (...) Antibiotics as part of the management of severe acute malnutrition. Severe acute malnutrition contributes to 1 million deaths among children annually. Adding routine antibiotic agents to nutritional therapy may increase recovery rates and decrease mortality among children with severe acute malnutrition treated in the community.In this randomized, double-blind, placebo-controlled trial, we randomly assigned Malawian children, 6 to 59 months of age, with severe acute malnutrition to receive

Full Text available with Trip Pro

2013 NEJM

53. Diarrhoea - antibiotic associated

work or school until they have been free from diarrhoea for 48 hours. Have I got the right topic? Have I got the right topic? From age 18 years onwards. This CKS topic covers the management of antibiotic-associated diarrhoea, including Clostridium difficile . This CKS topic does not cover the management of acute gastroenteritis (including presumed infectious gastroenteritis) in adults and children, diarrhoea due to food poisoning, or traveller's diarrhoea. These are covered in the CKS topics (...) , see the CKS topic on . Exclude other potential causes of diarrhoea or contributing factors. Ask about recent contact with anyone with acute diarrhoea and/or vomiting, exposure to a known source of enteric infection (possibly contaminated water or food), recent travel abroad, or a visit to a petting farm. Check for drugs (other than antibiotics) known to cause diarrhoea (for example proton pump inhibitors — also a possible risk factor for Clostridium difficile infection) or exacerbate diarrhoea

2013 NICE Clinical Knowledge Summaries

54. Food Preparation Effects on Gut Bacteria in Patients on Peritoneal Dialysis

by (Responsible Party): Icahn School of Medicine at Mount Sinai Study Details Study Description Go to Brief Summary: This is an intervention study of the effects of food preparation on the gut bacteria in patients with end stage renal disease on peritoneal dialysis. This is a dietary intervention consistent of consuming low amounts of advanced glycation end products (AGEs), the products of protein and sugar interaction during food processing and preparation using high direct heat. Condition or disease (...) : No Criteria Inclusion Criteria: Age > 18 years. Patients with ESRD on PD. Patients are able to understand and give consent. Patients with estimated daily dietary AGE intake > 12 AGE Eq/day (12,000 kiloUnits/day) based on 3-day food records. Exclusion Criteria: Patient on antibiotics in the last three months. Liver cirrhosis, and heart failure with EF < 30%. The use of chemotherapy, immunosuppressive medications, probiotics, and steroid in the last month. Oral iron supplementation in the last month

2015 Clinical Trials

55. Novel and disruptive biological strategies for resolving gut health challenges in monogastric food animal production (PubMed)

Novel and disruptive biological strategies for resolving gut health challenges in monogastric food animal production Use of feed antibiotics as growth promoters for control of pathogens associated with monogastric food animal morbidity and mortality has contributed to the development of antimicrobial resistance, which has now become a threat to public health on a global scale. Presently, a number of alternative feed additives have been developed and are divided into two major categories (...) alternative feed additives typically have no direct detoxification effects on endotoxin lipopolysaccharides (LPS) and this is likely the major reason that their effects are limited. It is now understood that pathogenic bacteria mediate their negative effects largely through LPS interactions with toll-like receptor 4, causing immune responses and infectious diseases. Therefore, disruptive biological strategies and a novel and new generation of feed additives need to be developed to replace feed antibiotic

Full Text available with Trip Pro

2015 Animal Nutrition

56. Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring? (PubMed)

trials published so far confirms that clarithromycin and rifampicin significantly impair the bioavailability of dabigatran, whereas clarithromycin, erythromycin, fluconazole, and ketoconazole alter the metabolism of rivaroxaban in vivo. Because of their more recent development, no published data were found for apixaban and edoxaban, or for potential interactions of DOACs with other and widely used antibiotics. It is noteworthy, however, that an online resource based on Food and Drug Administration (...) , there are several scenarios in which testing should be applied. The potential for drug-to-drug interaction is one plausible but currently underrecognized indication for laboratory assessment of the anticoagulant effect of DOACs. In particular, substantial concern has been raised during Phase I studies regarding the potential interaction of these drugs with some antibiotics, especially those that interplay with permeability glycoprotein (P-gp) and cytochrome 3A4 (CYP3A4). A specific electronic search on clinical

2014 Seminars In Thrombosis And Hemostasis

57. Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects

) Primary Purpose: Treatment Official Title: A Single-Center, Three-Part, Open Label Study to Evaluate the Relative Bioavailability of Two Formulations, Food Effect, and Interaction With Itraconazole Following Single Dose of GSK2140944 in Healthy Subjects and Effect of Food on Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of GSK2140944 in Healthy Elderly Subjects Actual Study Start Date : January 28, 2014 Actual Primary Completion Date : August 21, 2014 Actual Study Completion Date (...) on this site. Keywords provided by GlaxoSmithKline: pharmacokinetics GSK2140944 tolerability drug interaction safety itraconazole elderly healthy subjects food effect relative bioavailability Additional relevant MeSH terms: Layout table for MeSH terms Bacterial Infections Itraconazole Hydroxyitraconazole Antifungal Agents Anti-Infective Agents 14-alpha Demethylase Inhibitors Cytochrome P-450 Enzyme Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Steroid Synthesis Inhibitors

2014 Clinical Trials

58. Diet / Gut Microbiome Interaction and Influence on Inflammatory Disease in HIV Patients

Diet / Gut Microbiome Interaction and Influence on Inflammatory Disease in HIV Patients Diet / Gut Microbiome Interaction and Influence on Inflammatory Disease in HIV Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Diet / Gut Microbiome Interaction and Influence on Inflammatory Disease in HIV Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02610374 Recruitment Status : Recruiting First Posted : November

2015 Clinical Trials

59. Identification of Drug-drug Interaction Between Tacrolimus and Mycophenolate Mofetil in Healthy Adults

Identification of Drug-drug Interaction Between Tacrolimus and Mycophenolate Mofetil in Healthy Adults Identification of Drug-drug Interaction Between Tacrolimus and Mycophenolate Mofetil in Healthy Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Identification of Drug-drug Interaction Between Tacrolimus and Mycophenolate Mofetil in Healthy Adults The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02743247 Recruitment Status : Completed First Posted : April 19, 2016 Last Update Posted : April 19

2015 Clinical Trials

60. A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects

automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Layout table for additonal information Responsible Party: Nivalis Therapeutics, Inc. ClinicalTrials.gov Identifier: Other Study ID Numbers: N91115-1H-04 (SNO-5) First Posted: July 16, 2015 Last Update Posted: November 7, 2016 Last Verified: November 2016 Keywords provided by Nivalis Therapeutics, Inc.: N91115 Rifampin drug interaction Cavosonstat Additional relevant MeSH terms: Layout table for MeSH terms Rifampin Antibiotics (...) A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>